As delighted as I was to see the AS announcement, this one, 'Daffodil' is left field and very exciting.
Why would our US partner jump in with more money for another trial if they weren't fairly confident of the upcoming P3 results.
In fact, they may be seeing some interesting data in the younger girls in the P3 trial/s - hence this trial.
Now I am getting a bit excited.
Of course, not financial advice.
Ann: Trofinetide Rett syndrome clinical trial in girls aged 2-5, page-5
-
- There are more pages in this discussion • 26 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$22.14 |
Change
1.150(5.48%) |
Mkt cap ! $2.829B | |||
| Open | High | Low | Value | Volume |
| $21.50 | $22.44 | $21.50 | $13.15M | 598.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 437 | $22.12 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $22.15 | 8325 | 7 |
View Market Depth
| Last trade - 16.10pm 17/07/2024 (20 minute delay) ? |
| NEU (ASX) Chart |